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Ipilimumab is a fully human antibody that blocks
CTLA-4 and has proven to extend overall survival in
patients with unresectable stage III or stage IV mela-
noma. There is a need for well-documented pharmaco-
dynamic markers together with potential predictive
biomarkers that may allow for pretreatment selection of
patients and screening for IRAE. Most of the recently
published immune monitoring studies focus mainly on
the effect that Ipilimumab has on T cell populations. To
date, little information is available on the possible
impact that Ipilimumab treatment may have on MDSC
populations and their suppressive mechanisms. In order
to evaluate these effects, we conducted an in-depth
immune monitoring study centered on peripheral blood
MDSC populations as well as T cells in advanced mela-
noma patients undergoing treatment with Ipilimumab.
Six patients with advanced stage melanoma received
Ipilimumab treatment at 3 or 10 mg/kg doses as part
of an ongoing double blind randomized trial (BMS
trial CA184-169). Twenty-two additional patients
received 3 mg/kg doses. Blood samples were collected
from each patient before treatment and at the time of
the second and fourth Ipilimumab doses.
ICOS+CD4+ T cell frequency was significantly increased
after Ipilimumab treatment, suggesting an increase in the
activation of this cellular population. Analysis of circulat-
ing Treg frequencies revealed an initial increase, signifi-
cantly decreasing after the second Ipilimumab dose. The
endpoint mean frequency of Tregs was significantly lower
than the baseline.
Changes in MDSC populations with granulocytic and
monocytic phenotype (Lin-HLA-DR-/loCD15+ CD33
+CD11b+ and Lin-HLA-DR-/loCD14+, respectively) were
monitored and the results showed that after the first
dose, the granulocytic MDSC population significantly
decreased, remaining low at week 9. This decrease was
accompanied by a significant decrease in the population
of ARG1+ myeloid cells.
Further analysis showed that the populations of granu-
locytic MDSCs and CD4+ICOS+ T cell populations pre-
sented a statistically significant correlation.
These results provide a first look at the early
responses of peripheral blood myeloid cell populations
to Ipilimumab treatment. CTLA-4 blockade may be act-
ing upon the granulocytic MDSC population reducing
its frequency and functionality as soon as three weeks
after administration of the first Ipilimumab dose. The
mechanisms by which these in trans effects are taking
place should be further explored as well as their possible
relations to clinical benefit.
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